Discover
TRVI
Trevi Therapeutics, Inc.
17.61
2 x 13.36
2 x 22.46
bid
ask
-
1.04
5.58%
2 @ 05:59 AM
17.72 +0.11 (0.64%)
| Ytd | 40.65% | |
| 1y | 208.95% |
17.51
day range
18.90
5.53
52 week range
19.26
| Open | 18.59 | Prev Close | 18.65 | Low | 17.51 | High | 18.90 | Mkt Cap | 2.50B |
| Vol | 2.91M | Avg Vol | 1.81M | EPS | -0.32 | P/E | N/A | Forward P/E | -33.44 |
| Beta | 1.05 | Short Ratio | 13.90 | Inst. Own | 98.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 14.87 | 200-d Avg | 12.22 | 1yr Est | 23.90 |
| Income Statement | |||
| Operating Expenses | 14.91M | ||
| Research and Development Expense | 9.94M | ||
| Selling, General and Administrative Expense | 4.97M | ||
| Operating Income | -14.91M | ||
| Income Tax Expense | -20.00K | ||
| Net Income | -13.19M | ||
| Net Income Common Stock | -13.19M | ||
| Net Income Common Stock (USD) | -13.19M | ||
| Consolidated Income | -13.19M | ||
| Earnings per Basic Share | -0.09 | ||
| Earnings per Basic Share (USD) | -0.09 | ||
| Earnings per Diluted Share | -0.09 | ||
| Earning Before Interest & Taxes (EBIT) | -13.21M | ||
| Earning Before Interest & Taxes (USD) | -13.21M | ||
| Weighted Average Shares | 145.59M | ||
| Weighted Average Shares Diluted | 145.59M | ||
| Balance Sheet | |||
| Cash and Equivalents | 19.41M | ||
| Cash and Equivalents (USD) | 19.41M | ||
| Investments | 152.37M | ||
| Investments Current | 152.37M | ||
| Current Assets | 176.12M | ||
| Property, Plant & Equipment Net | 875.00K | ||
| Total Assets | 179.61M | ||
| Debt Current | 318.00K | ||
| Total Debt | 682.00K | ||
| Current Liabilities | 7.12M | ||
| Debt Non-Current | 364.00K | ||
| Total Liabilities | 7.48M | ||
| Accumulated Retained Earnings (Deficit) | -343.00M | ||
| Accumulated Other Comprehensive Income | -190.00K | ||
| Shareholders Equity | 172.13M | ||
| Shareholders Equity (USD) | 172.13M | ||
| Assets Non-Current | 3.49M | ||
| Total Debt (USD) | 682.00K | ||
| Liabilities Non-Current | 364.00K | ||
| Trade and Non-Trade Payables | 2.22M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 34.00K | ||
| Net Cash Flow from Financing | 222.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 498.00K | ||
| Capital Expenditure | -102.00K | ||
| Issuance (Purchase) of Equity Shares | 222.00K | ||
| Net Cash Flow from Investing | 16.97M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 17.07M | ||
| Net Cash Flow from Operations | -16.69M | ||
| Share Based Compensation | 2.19M | ||